{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-008045","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.809859+00:00","generated_at":"2026-06-05T07:18:35.003764+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ginkgo Bioworks FY2023 revenue $251M (-47% YoY); guides FY2024 total revenue $215-235M","bullets":["Cell Engineering services revenue $139M (+31% YoY); added 78 new Cell Programs in 2023.","Biosecurity revenue $108M (-68% YoY) as K-12 testing ramped down; shifting to recurring model.","Q4 2023 total revenue $35M (-65% YoY); Q4 Adj. EBITDA loss $(96)M vs. $(76)M prior year.","Cash balance $944M; FY2024 guidance: 100-120 new Cell Programs; total revenue $215-235M.","Acquired Patch Biosciences, Proof Diagnostics, Reverie Labs; launched Technology Network of 25+ partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-008045","json":"https://secwatch.observer/filing/0001628280-24-008045.json","markdown":"https://secwatch.observer/filing/0001628280-24-008045.md","text":"https://secwatch.observer/filing/0001628280-24-008045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/0001628280-24-008045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/dna-20240229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:18:35.003764+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8ad6311a9e5d938b9dc8d9d606dd76ffd455023c","claim":"Ginkgo Bioworks Holdings, Inc. reported financial results for fourth quarter 2023 and year ended December 31, 2023.","evidence_excerpt":"On February 29, 2024, Ginkgo Bioworks Holdings, Inc. issued a press release announcing its financial results for the fourth quarter 2023 and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024008045/0001628280-24-008045-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter 2023 and year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}